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Abstract
Background: Evidence-based recommendations about anticoagulation in acute type B aortic dissection (TBAD) are
completely missing, but there is a diffuse conviction that it could prevent the healing process of the dissected aorta’s
false lumen. However, several clinical conditions may lead to the necessity to start anticoagulant therapy among
patients with acute type B aortic dissection, ranging from atrial fibrillation to more complicated clinical scenarios and
the correct management in this kind of patients is still an open issue.
Case presentation: We are presenting a 51-years-old man with multi-infarct encephalopathy referred to us for an
acute TBAD and a first diagnosis of ischemic cardiomyopathy complicated by left ventricular (LV) thrombus formation.
Coronary angiography revealed a critical stenosis of left anterior descending artery (LAD) treated with drug-eluting
stent deployment. The patient was addressed to triple antithrombotic therapy with acetylsalicylic acid, clopidogrel and
warfarin with target INR 2.0–2.5. After 6 months, computed tomography angiography revealed the stability of the
dissection flap. Cardiac magnetic resonance imaging, however, confirmed the persistence of a small thrombotic
formation in LV apex, thus double antithrombotic therapy with warfarin and clopidogrel was instituted. The patient
remained asymptomatic during the follow-up period but was advised to suspend his job and physical activities.
Conclusion: Current guidelines do not discuss anticoagulant therapy in the setting of TBAD and large randomized
trials are lacking. Despite it is generally considered unsafe to administer anticoagulants in patients with TBAD, we
present a case in which triple antithrombotic therapy was well tolerated and did not lead to progression of the intimal
flap after 6 months.
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Background
The incidence of acute aortic dissection in the general
population is estimated to be about 2.5% per 100,000
person-years [1].
Uncomplicated patients with acute type B aortic dissection
are often successfully managed conservatively with a lifelong
anti-impulse therapy and serial imaging evaluation, in order
to minimize aortic wall stress and to detect extension of the
dissection or aneurysm formation respectively. Surgical or
endovascular treatment is usually reserved for patients devel-
oping complications related to dissection. Even though
current guidelines consider patent false lumen as a predictor
of aortic growth and poor outcome, there is no mention
about the management of antithrombotic or anticoagulant
therapy in the setting of aortic dissection [2]. This lack of
data is further attested by a relevant interdisciplinary expert
consensus on management of type B aortic dissection giving
no information about anticoagulation/antiplatelet therapy in
this scenario, also due to the large heterogeneity existing
among different studies [3]. This substantial gap of evidence
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compels the physicians to deal with such critical setting with-
out a shared or evidence-based strategy to be pursued.
We report a case of acute TBAD diagnosed along with
new-diagnosis of ischemic cardiomyopathy complicated
by left ventricular thrombotic formation and patent for-
amen ovale (PFO) in the setting of multi-infarct enceph-
alopathy. This case outlines the relevance of an
individual patient-tailored therapy and further stresses
the need of future studies and a consensus about the
role of anticoagulant therapy in patients with acute aor-
tic dissection.
Case presentation
A 51-year-old man was referred to this hospital for a
follow-up cardiology visit after a right cerebellar ische-
mia occurred 1 month prior to presentation, from which
the patient had rapidly recovered without residual defi-
cits. He had no history of hypertension, arthritis, uveitis,
mouth ulcers nor crystalline lens subluxation. He had
been smoking until 2 years before presentation; his an-
amnesis was negative for alcohol or illicit drug abuse
and his family history was unremarkable. His only medi-
cation was acetylsalicylic acid.
During the previous hospital stay, extensive examina-
tions had been performed, including electrocardiogram
(ECG), lipid panel, transthoracic echocardiography
(TTE) and doppler ultrasonographic assessment of the
supra-aortic vessels and of the lower extremities’ veins,
all of which resulted unremarkable.
A few days after hospital discharge, the patient had
suffered a single episode of intense subjective vertigo,
tinnitus, confusion and orthostatic imbalance, which had
resolved spontaneously in about 20 min without refer-
ring to any physician.
On presentation the patient was asymptomatic, eup-
neic and apyretic. His blood pressure was 155/90 mmHg
on both arms. On physical examination a mild pectus
excavatum was noticed. Cardiac tones were valid and
regular, and a third tone was heard. Radial pulses were
symmetrical and valid, while the femoral and pedidial
pulses were slightly attenuated.
The ECG revealed a sinus rhythm at 66 bpm with nor-
mal atrioventricular and intraventricular conduction; a
Q wave was documented in leads D2, aVF, D3, V5 and
V6 and a negative symmetrical T wave was present in
the same leads (Fig. 1); these signs were absent in
Fig. 1 Admission ECG showing Q waves in leads D2, aVF, D3, V5 and V6 and a negative symmetrical T wave in the same leads
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previous ECGs. A TTE was performed, which docu-
mented a moderate depression of the left ventricular
ejection fraction (LVEF) (39%) and infero-posterior and
apical akinesia with left intraventricular “smoke”. The
patient was thus admitted to the hospital ward for fur-
ther investigations.
On admission blood tests were mostly within normal
range, including haemoglobin (13,8 g/dL), C-reactive pro-
tein (2,4mg/L), high-sensitivity troponin T measurement
(12 ng/L, upper limit of normal 50 ng/L), creatine
phosphokinase (90 UI/L), creatinine (0,99mg/dL), urea
(31mg/dL), aspartate transaminase (16 UI/L), alanine
transaminase (12 UI/L), total bilirubin (0,6mg/dL), INR
(1,02), aPTT ratio (0,95), fibrinogen (292mg/dL). N-
terminal prohormone of brain natriuretic peptide was
slightly elevated (636 pg/mL, upper limit of normal 300
pg/mL).
Because of the recent stroke, the patient’s rhythm was
monitored with ECG telemetry during the whole
hospitalization period in order to exclude silent paroxys-
mal atrial fibrillation episodes. Besides, a transcranial dop-
pler was performed, which documented the presence of a
moderate right-to-left shunt. Moreover, the transoesopha-
geal echocardiography (TEE) showed a PFO (Fig. 2) along
with a double lumen in the descending thoracic aorta, ris-
ing the suspicion of aortic dissection. Consequently a
computed tomography angiography (CTA) was performed
documenting a TBAD extending from the thoracic de-
scending aorta just below the origin of the left subclavian
artery to the iliac arteries bilaterally, the false lumen pre-
vailing over the true lumen (Fig. 3). The right renal artery
and the inferior mesenteric artery originated from the
false lumen, whereas the left renal artery, the superior
mesenteric arteries and the celiac trunk all originated from
the true lumen; the supra-aortic trunks and the ascending
aorta were not involved in the dissection process. Within
the coronary vessels, the CTA documented one-vessel dis-
ease with two small eccentric plaques in the proximal left
anterior descending (LAD) artery conditioning a moderate
stenosis (> 50%). A hypodense area was observed in the
subendocardial ventricular myocardium at the apical and
middle segments of the inferior wall and at the middle
segment of the anterolateral wall; no pericardial effusion
was documented. A cardiac magnetic resonance (MR) was
then carried out, which showed the presence of ischemic
apical, apical-anterior and inferior late-gadolinium en-
hancement along with intraventricular thrombosis and se-
vere left ventricular systolic disfunction (Fig. 4).
Venous ultrasound of the lower limbs was normal.
Because of the recent episode of dizziness and ortho-
static imbalance, following neurologist review, a brain
MR was also performed, documenting multiple areas of
altered signal due to previous old and recent ischemic
events in the cerebellar and cerebral hemispheres (Fig.
5).
Takayasu arteritis, giant cell arteritis and rheumatic dis-
eases were considered in the differential diagnosis [4]; a
rheumatologic screening was performed, including com-
plement components, rheumatoid factor, anti-nuclear
antibodies, anti-neutrophil cytoplasmic antibodies, anti-
cardiolipin antibodies and β2-glycoprotein 1 antibodies,
all of which resulted within the range of normality.
A thrombophilic screening was performed, including
tests for protein C and protein S deficiencies, factor V
Fig. 2 Transesophageal 3D echocardiographic view showing the patent foramen ovale (light blue arrow)
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Leiden and prothrombin 20,210 mutations, antithrombin
deficiency, hyperomocysteinemia and antiphospholipid
syndrome, and resulted negative.
The presence of mild pectus excavatum along with a
history of surgery for foot deformity raised suspicion for
collagen diseases such as Marfan and Ehlers-Danlos syn-
drome [4]; the genetic experts, however, due to the lack
of significant physical signs of collagen disease and the
absence of aortic root aneurysm and ectopia lentis [5],
considered these diagnoses unlikely and genetic testing
was not recommended.
From a cardiovascular point of view, two theories were
hypothesized. According to the first one, the patient had
suffered from a silent recent type 1 myocardial infarction
leading to LVEF reduction with consequent thrombus
formation in the left ventricle and subsequent
embolization to the brain causing multi-infarct enceph-
alopathy [6]; in this scenario, the PFO would be a mere
bystander. The second theory infered that the patient
had suffered from deep vein thrombosis from unknown
origin, causing encephalic and myocardial infarction on
embolic basis due to the right-to-left shunt of the PFO;
in this latter case, the atherosclerotic LAD stenosis
would be an incidental finding. Unfortunately, whatever
the main event was, either the recent myocardial infarc-
tion or the deep vein thrombosis, the question remained
unsolved due to its silent course.
Following discussion between the cardiologist, the
interventional radiologist and the cardiac surgeon, after
multiple interviews with the patients regarding risks and
benefits of the different treatment options, it was jointly
decided not to perform endovascular treatment regard-
ing the aortic dissection due to the lack of symptoms
and the absence of parenchymal involvement, but careful
monitoring was deemed necessary and strenuous exer-
cise was contraindicated [2]. A coronary angiography
exam was then performed showing 50% stenosis of the
proximal LAD coronary artery at angiographic estima-
tion (Fig. 6a) with patency of its distal segment (Fig. 6b);
a “minus” image along with slow-flow appearance distal
to the lesion raised suspicion for coronary artery dissec-
tion and induced the operator to evaluate the stenosis
with intravascular ultrasound imaging, which revealed a
critical minimal lumen area of 4,0 mm2 with 80% plaque
burden (Fig. 6c) as compared to the patent lumen of the
adjacent segment (Fig. 6d). Due to the high-risk features
of the coronary lesion, after communicating benefit and
risk information to the patient and acquiring informed
consent, the operator performed angioplasty with the de-
ployment of a Synergy™ drug-eluting stent. The patient
was started on triple antithrombotic therapy with
Fig. 3 a Axial CTA view showing the TBAD with the false lumen (asterisk) clearly prevailing over the true lumen (hash). b CTA 3D-scan documenting
the extension of the TBAD, originating from the thoracic descending aorta just below the origin of the left subclavian artery (light blue arrow) to the
iliac arteries bilaterally
Fig. 4 Delayed-enhancement cardiac MR image showing apical
intraventricular thrombosis (orange arrow) and late gadolinium
enhancement (blue arrows) in the four-chamber view
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Fig. 5 Brain T2-FLAIR MRI scans showing multiple areas of ischemia (light blue arrows) in the cerebellar and cerebral hemispheres. a Recent
ischemic lesions in the lower left cerebellar hemisphere. b Old ischemic lesion in the upper right cerebellar hemisphere. c Recent ischemic
lesions in the right frontal and left temporo-occipital cerebral regions
Fig. 6 a Coronary angiography view showing 50% stenosis (orange arrow) of the proximal LAD coronary artery. b Coronary angiography view
showing a long type 3 LAD coronary artery (light blue arrows) with patency of its distal portion. c IVUS image showing a minimal lumen area of
4.0 cm2 with high plaque burden (80%). d IVUS image showing patency of the segment adjacent to the LAD coronary artery stenosis
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warfarin (because of the left ventricular thrombus),
acetyl-salicylic acid and clopidogrel; low-molecular-
weight heparin bridging was utilized until target INR
(2.0–2.5) was achieved. The PFO closure procedure was
temporarily postponed [7].
During the hospital stay the patient remained asymp-
tomatic. Cardiac anti-remodelling therapy with angioten-
sin converting enzyme inhibitor and a potassium sparing
diuretic was started and it was well tolerated. No
arrhythmic events were documented on telemetry. At
discharge the patient was asymptomatic and in stable
haemodynamic condition.
After 1 month acetyl-salicylic acid was interrupted.
After 6 months the CTA showed no progression of the
aortic dissection (Fig. 7); LVEF was almost unchanged
(38%) on TTE and a small intraventricular thrombotic
formation, albeit reduced in diameter, still persisted on
cardiac MR imaging (Fig. 8). The patient was asymptom-
atic and he was advised to prolong his therapy with both
clopidogrel and warfarin until future assessment with
TTE and CTA after 12 months. PFO closure was not
deemed necessary as long as the patient was on anticoa-
gulation therapy.
Discussion and conclusion
Aortic dissection consists of a tear in the intimal layer of
the aortic wall, thus connecting the media with the aor-
tic lumen and allowing the blood to flow from the true
lumen, delimited by the intimal layer, into the false
lumen, localized between the intima and media of the
aortic wall [2]. High pressure within the aortic wall
causes the rupture to propagate either anterogradely or
retrogradely or both and can lead to hypoperfusion of
parenchymal organs and increasing risk of aortic rupture
[8].
According to Stanford’s classification, aortic dissec-
tions are classified as type A when they involve the
ascending aorta and as type B if only the descending
aorta is involved [9]. TBAD can further be subdivided
into complicated or uncomplicated depending on the
presence of at least one of the following: malperfusion
syndrome, aortic rupture, hypotension or shock, neuro-
logic sequelae, recurrent or refractory pain, hypertension
refractory to medical therapy, early aortic dilation or
propagation of the dissection [2]. The first-line treat-
ment of acute TBAD is “anti-impulse” therapy, which
consists of aggressive control of blood pressure. With re-
gard to the use and management of anticoagulants in
patients with TBAD, recommendations are completely
missing in current guidelines [2].
A study conducted by Akutsu et al. in 2004 showed
that patency of the false lumen is a strong independent
prognostic factor for dissection-related death in patients
with TBAD [10]. More recent reports, however, have
questioned this issue; Tsai et al. in 2007 showed that no
difference in mortality exists between TBAD patients
with complete thrombosis of the false lumen and pa-
tients with a completely patent false lumen, whereas par-
tial thrombosis of the false lumen was associated with a
significantly higher mortality as compared with patency
of the false lumen (HR 2.69, 95% CI 1.45–4.98, p-value
0.002) [11]. Nevertheless, several case reports in litera-
ture demonstrate the suitability and apparent safety of
anticoagulants in the setting of acute aortic syndrome
[12, 13]. Cañadas et al. described the absence of adverse
post-hospitalization outcomes in three patients with
intramural aortic hematoma and history of pulmonary
embolism or atrial fibrillation that were treated initially
with unfractionated heparin and then with warfarin,
concluding that in situations where anticoagulation is
necessary this treatment can be maintained without an
impact on the clinical or morphological evolution of the
intramural aortic hematoma [14]. Bhatty et al. described
a patient with chronic TBAD that suffered of pulmonary
Fig. 7 CTA image obtained 6months after the acute event showing no progression of the aortic dissection. a Axial view showing the false
lumen (asterisk) still prevailing over the true lumen (hash). b CTA 3D-scan showing the stability of the TBAD; the light blue arrow indicates the
origin of the dissection
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embolism and was treated with administration of intra-
venous heparin therapy and then discharged with war-
farin therapy for 3 months without complications [15].
Von Kodolitsch et al. showed that anticoagulation with
warfarin is feasible even in post-surgical patients with
type A aortic dissection as it did not affect aortic growth
and was not associated with late mortality nor with late
aortic events, thus suggesting that patients requiring
anticoagulation due to other indications should be in-
deed considered on individualized basis to receive such
treatment [16]. This holds true especially for atrial fibril-
lation, which is not uncommon among patients with
aortic dissection [17]; few reports have addressed the
issue of anticoagulation in this scenario with heteroge-
neous results and patient-tailored therapy seems the best
treatment option until larger studies will focus on this
topic [18, 19].
Our case presents a rare association of pathologies re-
quiring antithrombotic therapy in the context of acute
TBAD. The necessity to treat the proximal LAD stenosis
with the deployment of a drug-eluting stent in a patient
with intraventricular thrombosis required triple anti-
thrombotic treatment; after multidisciplinary assessment,
the risk of thromboembolism from the left ventricle and
the necessity to treat the coronary lesion were consid-
ered to outweigh the potential risk of dissection progres-
sion and aortic rupture given by false lumen patency
[20]. The aortic dissection was chosen not to be repaired
due to the uncomplicated course of the disease at this
point. PFO closure was not considered a priority any-
more due to the protection from further strokes granted
by anticoagulant agents and because the use of a device
for this procedure would prolong the duration of anti-
thrombotic treatment [7].
The evidence of a patent false lumen and the uncom-
plicated course of the aortic dissection after 6 months of
antithrombotic therapy show that, along with previous
reports [11–14], anticoagulation should not be consid-
ered an absolute contraindication in every patient with
TBAD but needs to be evaluated on a case-by-case basis.
To our knowledge no large randomized trial is being
conducted to face this relevant issue, thus this case sup-
ports the necessity of a multi-disciplinal consensus on
the management of anticoagulation therapy in TBAD
patients, which is a controversial matter often taken for
granted. We believe that the acute setting must be faced
with caution and the benefits of anticoagulation therapy
must be carefully balanced against the potential neces-
sity for surgical intervention due to dissection progres-
sion, which is difficult to estimate in the first hours, or
severe parenchymal suffering. Markers of parenchymal
organs damage must be frequently assessed and anticoa-
gulation therapy might be withheld in the hyperacute
setting until it is decided whether to medically or surgi-
cally treat the patient. When concomitant conditions re-
quire antithrombotic therapy and the risk of thrombosis
exceeds the risk of bleeding, short-acting anticoagulants
might be preferred in the acute setting due to their
shorter half-life and easier handling, should unpredict-
able conditions requiring anticoagulation interruption
arise; moreover, fast-acting anticoagulant agents, such as
unfractionated or low-molecular-weight heparin, could
provide a bridge to oral vitamin K antagonists, which
usually require a few days before adequate antithrom-
botic status is achieved. Heparin bridging proved safe
and feasible in our case, but no absolute recommenda-
tion can be given due to the absence of targeted studies.
At discharge oral anticoagulation therapy should be pre-
ferred over heparin-based drugs, due to its safety and
easier route of administration. As many different condi-
tions may require the use of anticoagulation therapy, no
absolute statement can be given as for the duration of
this therapy; reversible thrombotic conditions might re-
quire shorter anticoagulation duration, whereas irrevers-
ible conditions, such as permanent atrial fibrillation,
might require indefinite anticoagulation. Randomized
studies regarding the use of novel oral anticoagulants in
patients with aortic dissection are lacking; for this rea-
son, no recommendation can be given about which type
of anticoagulant agent should be preferred. A case report
by Turgay Yıldırım et al., however, shows that dabiga-
tran might be safe in the setting of TBAD and we believe
that novel oral anticoagulants might be used in this sce-
nario as well [19]. Nevertheless, studies are needed to
specifically address this issue. As the aortic dissection
Fig. 8 Early-enhancement cardiac MR image acquired 6 months
after the acute event showing the presence of a tiny apical stratified
thrombus (orange arrow) in the four-chamber view
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becomes chronic, periodic imaging examinations must
be performed in order to assess the stability and exten-
sion of the dissection and false lumen patency and antic-
oagulation therapy should be managed accordingly after
ischemic and bleeding risk assessment.
In conclusion, despite it is generally considered unsafe
to administer anticoagulants in patients with type B aor-
tic dissection, very few studies focused on this subject
and different reports state that anticoagulant therapy
might be harmless or might even improve the prognosis
of this set of patients. Each TBAD patient requiring
anticoagulation should be approached individually, care-
fully balancing ischemic and bleeding risks, which
should be extensively discussed with the patient; a per-
sonalized assessment and multidisciplinary decision-
making is a key issue in this regard. However, there is a
large evidence gap and uncertainty in this context and
trials in this arena are urgently needed.
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